HIV-1 rev Antisense Phosphorothioate Oligonucleotide Binding to Human Mononuclear Cells Is Cell Type Specific and Inducible

Samuel Jay Pirruccello, G. A. Perry, P. J. Bock, M. S. Lang, S. M. Noel, G. Zon, P. L. Iversen

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

A fluorescein-conjugated, antisense phosphorothioate oligonucleotide with specificity for HIV-1 rev sequence (FAM-anti-rev) was investigated for its ability to bind to specific subsets of human peripheral blood mononuclear cells. Oligonucleotide binding by CD4+ and CD8+ T cells, B cells, and monocytes isolated from 15 normal and 15 HIV-infected individuals was evaluated on both nonstimulated mononuclear cells and after 24-hr activation with phytohemagglutinin (PHA). In both normals and HIV-infected individuals, we found a significantly higher percentage of monocytes and B cells binding oligonucleotide in comparison to T cells. Oligonucleotide binding by both T cells and B cells was enhanced by 24-hr PHA stimulation while monocyte uptake was unchanged. In comparison to normal controls, HIV-1-infected patients showed slightly higher percentages of both unstimulated and PHA activated CD4+, CD8+, and CD25+ T cells binding oligonucleotide. The propensity for a high percentage of monocytes, which may act as an HIV-1 reservoir, to bind the anti-rev oligonucleotide and the enhanced binding by T cells in the HIV-1-infected patient samples provides some optimism for potential in vivo therapy of HIV-1 infection using antisense oligonucleotides.

Original languageEnglish (US)
Pages (from-to)285-289
Number of pages5
JournalAntisense Research and Development
Volume4
Issue number4
DOIs
StatePublished - Jan 1 1994

    Fingerprint

ASJC Scopus subject areas

  • Genetics

Cite this